Chengde

Researchers are evaluating the safety, tolerability, and effectiveness of RAY1225 in adults with obesity. This phase 2 study aims to learn about how well participants tolerate RAY1225 and also explores how it may help with weight loss. The study is expected to last about six months for each participant and is sponsored by Guangdong Raynovent Biotech Co., Ltd. Participants will be randomly assigned to receive either one of two doses of RAY1225 or a placebo. The treatments are given by subcutaneous injection once every two weeks for 24 weeks. There are two groups receiving escalating doses of RAY1225 and two placebo groups, all following the same dosing schedule. During the study, participants will be monitored for changes in body weight and waist circumference from the start of the study to week 26. Researchers will also track the percentage of participants who achieve weight loss of 5%, 10%, or 15%. Assessments will include safety and tolerability evaluations throughout the treatment period. The total participation time for each person is about six months.

Researchers are evaluating Senl-T7 CAR T cells in patients with relapsed or refractory CD7 acute T lymphoblastic leukemia or T lymphoblastic lymphoma. This open, prospective, dose-escalation clinical study aims to assess the safety and effectiveness of Senl-T7 while collecting pharmacokinetic and pharmacodynamic data to better understand its behavior in the body. Participants will receive preconditioning treatment before being infused with the Senl-T7 CAR T cells, which include components targeting CD7 on cancer cells. After infusion, patients will be closely monitored for adverse reactions and treatment response to evaluate safety and remission rates. During the study, patients will undergo regular evaluations, including monitoring for side effects within the first month and assessing remission status at three months post-infusion. Researchers will track adverse events and treatment outcomes to determine the impact of Senl-T7 on the disease. Participation duration can extend up to several months as outcomes are measured over time.